Experienced Team in Place to Drive Late-Stage Development of Innovative Single-Tablet Regimens for HIV Infection SOUTH SAN FRANCISCO, Calif., Sep 10, 2012 -- Tobira Therapeutics, Inc., developer of ...
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months. 3.
(Reuters) - Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, ...
Tobira Therapeutics and Dong-A said today they have inked a pair of licensing agreements for evogliptin and cenicriviroc (CVC). The deals are in connection with development programs the companies plan ...
Mark Lampert‘s Biotechnology Value Fund LP recently filed a 13G with the US SEC to report lowering its stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) to 399,433 shares, which amass 2.1% of the float.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results